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Abstract
Lysis of fibrin was first recognized by MORGAGNI in 1769, observing a liquid blood in
a patient of acute death, and the phenomenon was named as fibrinolysis by DASTRE in 1893.
In 1937, MACFARLANE recognized in a patient after cholecystectomy that the blood clot was
lysed completely in the following morning. Since then, much attention has been paid clinically
on fibrinolysis and it has been said to occur in case receiving a large amount of blood transfusion,
shock, cancer, obstetric diseases, hemophilia, various drug poisonings, allergic diseases, after
irradiation and after the operations of lung, pancreas and prostate. In our department, also, the
similar phenomenon was recognized often in association with cardiac surgery using the artificial
heart-lung machine, and a difficulty in hemostasis was encountered postoperatively. We have been
studying, therefore, on fibrinolysis in open heart surgery.
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Lysis of fibrin was first recognized by MORGAGNI in 1769, observing
a liquid blood in a patient of acute death, and the phenomenon was
named as fibrinolysis by DASTRE in 1893. In 1937, MACFARLANE recognized
in a patient after cholecystectomy that the blood clot was lysed completely
in the following morning. Since then, much attention has been paid
clinically on fibrinolysis and it has been said to occur in case receiving a
large amount of blood transfusion, shock, cancer, obstetric diseases, hemo-
philia, various drug poisonings, allergic diseases, after irradiation and
after the operations of lung, pancreas and prostate.
In our department, also, the similar phenomenon was recognized
often in association with cardiac surgery using the artificial heart-lung
machine, and a difficulty in hemostasis was encountered postoperatively.
We have been studying, therefore, on fibrinolysis in open heart surgery.
For prophylaxis and treatment of fibrinolysis, various substances have
been used for a long time, such as fibrinogen, fresh blood, serum albumin
fraction, anti-hemophilic globulin, soy-bean inhibitor, cortisone, platelet
transfusion and various hemostatics. However, in 1954, OKAMOTO intro-
duced e-aminocaproic acid (EACA) which was found to have a strong
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anti-fibrinolytic action, and then it has been widely used as a therapeutic
agent. Then, OKAMOTO et at. (1965) introduced a trans-stereoisomer of
4.aminomethyl cyclohexane carboxylic acid (AMCRA) which has stronger
anti-fibrinolytic activity than EACA (Fig. 1).
We used AMCRA both experimentally and clinically in 23 cases, and
compared its activity with that of EACA.
(A) Experimental evaluation
(1) Thrombelastography
One hundred units of streptokinase (SK) was added to 1 ml of normal
citrated plasma, and then calcium ion was added to observe the throm.
belastograms (TEG). The plasma having 3 minutes of the lysis time was
used for the experiments. EACA or AMCRA was added in various con-
centrations before 100 unitsjml of SK was mixed to plasma for the purpose
of obtaining TEG (Photographs 1, 2, Table 1).
The lysis time of the SK activated plasma containing 1 l~gjml of
Photograph 1
1. SK lOOu/ml+EACA lO/-lg/ml added
2. SK lOOu/ml+EACA 25/-lg/ml added
3. SK lOOu/ml+EACA 50/-lg/ml added
Photograph 2
2. SK 100u/ml+AMCHA 0.1 ng/ml added
2. SK 100u/ml+AMCHA 1.0/-lg/ml added
3. SK lOOu/ml+AMCHA 1O.0/-lg/ml added
Table 1
Solutions added to the plasma
k Lysis time-----
I
r rna
SK EACA
I
AMCHA (min.) (min.) (mm) (min.)(u/ml) (/-lg/ml) (/-lg/ml)
100 0 0
I
5.0 / 2
I
3.0
100 10 0 5.0 / 12 I 10.0
100 25 0 5.0 6.0 21
I
long
100 50 0 4.0 10.0 25 /
100 0 0.1 4.0 / 6 I 4.5I
100 0 1.0 4.0 3.5 31
I
39.0
100 0 10.0 4.0 8.0 28 /
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AMCHA (39 minutes) varies in between that of the SK activated plasma
containing 101J.gjml of EACA (10 minutes) and that of the SK activated
plasma containing 25 fl.g/ml of EACA (immeasurably prolonged). Thus,
the activity of AMCHA is 10-25 times stronger than that of EACA.
(2) Euglobulin lysis time
Euglobulin fraction was prepared from the normal citrated plasma
by the method of VON KAULLA. Five units of SK was added to 1 ml of the
euglobulin solution, and thrombin was added to produce the clotting.
Then, the clot dissolved in a few minutes. On the next experiment, various
concentrations of EACA or AMCHA were added to the euglobulin solution
in advance, and then 5 units/ml of SK was added to determine the clot
lysis time.
When each value was plotted on the logarithmic graphs, EACA and
AMCHA showed straight lines in parallel (Fig. 2). The activity ratio of
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Fig. 2
AMCHA and EACA is, therefore, the same at any concentration. The
ratio of normal 3 samples was 5.3, 5.3 and 5.6 times, respectively. The
average value among 3 determinations was 5.4 in their activity.
(B) Evaluation on clinical cases
Among 3218 major surgical operations done in our department for
the past 7 years excluding cardiac surgery, increased fibinolysis was
recognized only in 8 cases (0.25 % i. e. esophageal carcinoma 1, gastric
carcinoma with Banti's syndrome 1, coarctation of the aorta 1, thoracic
aneurysm 1, pulmonary tuberculosis 1, bronchiectasis 2, Werlhof's disease
3
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1). On the contrary, increased fibrinolysis in open heart surgery was seen
in 7 out of 29 cases (24. 1%), as reported previously. Since we started to
use EACA prophylactically after the completion of the extracorporeal
circulation, increased fibrinolysis have been able to prevent in consecutive
250 cases. Through our various experiments, 0.25 gjkg of body weight of
EACA was reported to be adequate. Instead of using EACA, AMCHA
was given in two groups, receiving Ij5 dosis of EACA (0.05gjkg) and 1/10
that of EACA (0.025 gjkg) after perfusion (Tables 2, 3).
(1) Appearance of fibrinolysis
Whole blood clot lysis and TEG were used for the evaluation. None
of the cases receiving EACA and AMCHA showed increased fibrinolysis.
(2) Comparison of the amount of blood discharge through the intra-
thoracic drain
The amount of blood discharge through the drain was measured at
12 hours after the surgery and at the time of removing the drain in 18
cases without EACA and AMCHA, in 11 cases receiving 0.25 gjkg of
EACA, in 12 cases receiving 0.05 gjkg of AMCHA and in 11 cases
receiving 0.025 gjkg of AMCHA. The amount of blood discharge decreas.
ed in the order of non.treated group, EACA group, 0.025 gjkg AMCHA
group and 0.05 gjkgAMCHA group. At 12 hours after the operation, the
amount of blood discharge in EACA group was 42.2 % less than that of
Table 2
No.1 Nam, I Ag' I Sox I Diagnosis Operation
•
Perfusion I Lowest
t " (") temperaturelme mm. (OC)
IIM.K. II F I VSD Closure of the defect I 76 20.8
2 M.1. 5 F I VSD Closure of the defect 32 27.0
31 K.O.
I
9 F Aortic stenosis Dilatation of the I 151 20.2
o"'um
41 K.A. 19 F VSD Closure of the defect 13 28.6
5 M.H. 17 M Ruptured aneurysm Closure of the defect 70 21.6
of Valsalva's sinus
6 A.H. 3 F ASD Closure of the defect 10 33.7
7 M.M, 6 F VSD Closure of the defect 16 34.0
8 T.F. 16 M Right ventricular Radical operation
I
86 22.8
aneurysm
9 B.N. 17 M Mitral stenosis Commissurotomy 31 33.6
10 E.K. 11 F Mitral steno- Valuloplasty 81 33.4
insufficiency
II Y.l'. 12 F VSD Closure of the defect 87 26.0
I
121 M.T. 16 M
i
ASD Closure of the defect 18 33.8
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No.1 Namo I Ago ISox
I
Diagnosis Operation P"fu,ion I Low,,'f (.) temperaturelme mm. (OC)
13 T.A. I 35 M Mitral insufficiency Valvuloplasty 100 30.2
14 R.A.
I
5 M VSD Closure of the defect 88 27.8
15 S.N. 16 F ASD Closure of the defect 16 32.0
16 Y.N. 19 M VSD Closure of the defect 36 27.6
17 T.!. 21 M Aortic steno- Transplantation of 236 24.3
insufficiency the valve
Mitral stenosis Commissurotomy
18 T.O. 5 F ASD Closure of the defect 9 33.8
19 0.0. 26 M Aortic steno- Transplantation of 184 26.9
insufficiency the valve
Mitral stenosis Commissurotomy
20 T.O. 7 M ASD Closure of the defect 15 33.6
21 Y.M. 14 F ASD Closure of the defect 7 33.5
22 A.H. 7 M VSD Closure of the defect 31 32.2
23 M.U. IS M VSD Closure of the defect 22 34.5
non-treated group; in 0.025 gjkg AMCHA group 12.5 % less than that of
EACA group; in 0.05 gjkg AMCHA group 17.8 % less than that of
0.025 gjkg AMCHA group. The total amountof blood discharges obtained
until the removal of the drain showed the similar changes. Namely, the
amount of blood discharge in EACA group was 26.3 % less than that of
non-treated group; in 0.025gjkg AMCHA group 34.1 % less than that of
EACA group, in 0.05 gjkg AMCHA group 17.3 % less than that of 0.025
rn1/kg
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Fig. 3 Amount of blood discharge after operation
(a): 12 hours
(b): until the removal of drain
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g/kg AMCHA group. Thus, AMCHA appeared to be more effective than
EACA, and 0.05 g/kg AMCHA was the most adequate dose (Fig. 3).
(3) Comparison of englobulin lysis time
Hypothermia with extracorporeal circulation was used more in 0.05
g/kg AMCHA group than in 0.025 g/kg AMCHA group. Therefore, the
former group showed shortening of the lysis time before the administration
of AMCHA. On the administration of AMCHA, it varied from 30 min.
to 60 min. in 0.05g/kg AMCHA group, and from 82 min. to 114 min. in
0.025 g/kg AMCHA group. However, they all returned to normal value
1 hour after the operation (Fig. 4).
Euglobulin lysis time
Fig. 4
a: preoperative
b: post-thoracotomy
c: during extracorporeal circulation
d: after extracorporeal circulation
e: after AMCHA given
f: after protamine given
g: I hour after operation
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DISCUSSION AND CONCLUSION
On comparing the effects of EACA and AMCBA on fibrinolysis in
this experiment, TEG showed that AMCHA was 10-25 times more than
EACA. While in measuring the euglobulin lysis time it revealed that
AMCBA was 5.4 times more effective than EACA. In thrombelasto.
graphy, the plasma was used, in which inhibitors for fibrinolysis were
also included. In euglobulin lysis time test, however, it was measured
with euglobulin fraction which contained no inhibitors. Besides such a
6
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difference of methods, there are some differences in the mechanism of
their actions, so their effect might have been different with methods used.
Other authors also reported that AMCHA was 5-26 times more effective
than EACA.
When AMCHA was used in a dose of 1/5 that of EACA (0.05 g/kg)
or 1fl 0 (0.025 g/kg) on cardiac surgery using artificial heart-lung machine,
the amount of blood discharge through the intrathoracic drain was less
than in the group receiving EACA. Euglobulin lysis time became shortened
more in 0.05 g/kg AMCHA group than in 0.025 g/kg AMCHA group,
probably due to hypothermia combined with extracorporeal circulation,
while the amount of blood discharge was decreased in the former group.
This appeared to be due to a large dose of AMCHA used after extracorpo-
real circulation.
Thus, through the experimental results and clinical experiences, it is
concluded that AMCHA is very strong anti.fibrinolytic agent which in.
hibits the increased fibrinolytic activity after extracorporeal circulation
and the dose of AMCHA being 1/5-1/10 that of EACA is adequate.
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